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siRNA stabilized for in vivo applications is filtered and reabsorbed in the renal proximal tubule (PT), reducing mRNA expression
transiently. Prior siRNA efforts have successfully prevented upregulation of mRNA in response to injury. We proposed reducing
constitutive gene and protein expression of LRP2 (megalin) in order to understand its molecular regulation in mice. Using siRNA
targeting mouse LRP2 (siLRP2), reduction of LRP2 mRNA expression was compared to scrambled siRNA (siSCR) in mouse PT
cells. Mice received siLRP2 administration optimized for dose, administration site, carrier solution, administration frequency,
and administration duration. Kidney cortex was collected upon sacrifice. Renal gene and protein expression were compared by
qRT-PCR, immunoblot, and immunohistochemistry (IHC). Compared to siSCR, siLRP2 reduced mRNA expression in PT cells to
16.6%±0.6%. Inmouse kidney cortex, siLRP2 reducedmRNA expression to 74.8± 6.3% 3 h and 70.1± 6.3% 6 h after administration.
mRNA expression rebounded at 12 h (160.6 ± 11.2%). No megalin renal protein expression reduction was observed by immunoblot
or IHC, even after serial twice daily dosing for 3.5 days. Megalin is a constitutively expressed protein. Although LRP2 renal mRNA
expression reductionwas achieved, siRNA remains a costly and inefficient intervention to reduce in vivomegalin protein expression.
1. Introduction
RNA interference (RNAi) is an attractive approach to tran-
siently cleave mRNA transcripts and ultimately reduce pro-
tein expression [1, 2]. For a variety of therapeutic indications,
synthetic small interfering RNAs (siRNAs) have been modi-
fied to effectively mediate in vivo gene and resultant protein
expression regulation [3–8]. In the kidney, siRNA stabilized
with 2󸀠O-methylation is filtered and reabsorbed in the renal
proximal tubule (PT) following IV administration, reducing
relative mRNA expression temporarily in the PT [9]. siRNA
directed to candidate genes, including p53, has prevented
multiple forms of acute kidney injury (AKI) and renal fibrosis
in animal models [10–14].
Investigators have succeeded in reducing relative mRNA
expression and mitigating disease phenotypes through either
high-dose siRNA administration without a carrier molecule
or using lower doses bound to nanoparticles [15–18]. Regard-
less, a common theme is the prevention of candidate gene
upregulation in response to injury or disease. Many of these
studies reveal extended reductions in transcript expression;
however, these reductions are relative to a scrambled control
condition in the setting of gene upregulation. In contrast, we
proposed reducing gene and protein expression of a constitu-
tively expressed receptor, LRP2 (megalin), in order to better
understand the molecular regulation of this protein.
Megalin, encoded by LRP2, is a 600 kDa cell surface
endocytic receptor found in the apical membrane of renal
proximal tubule epithelial cells [19]. Megalin complexes with
cubilin and is important in the reabsorption of trace elements,
thyroglobulin, and carrier-bound vitamins [20]. Megalin
has been implicated in the uptake of several nephrotoxins,
including folate, cadmium, gentamicin, and colistin [21–24].
Receptor activated protein (RAP) and cilastatin have been
shown to block the reabsorption of these toxins through
megalin-mediated endocytosis [21, 22]. RNAi of LRP2 may
hold similar therapeutic potential.
Although megalin has an extended half-life [25], other
investigators have succeeded in providing serial daily or twice
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weekly administration of siRNA to reduce renal expression
of other genes and proteins [11–13]. We hypothesized that
serial administration could similarly reduce megalin expres-
sion. After significant optimization, successful knockdown
of LRP2 mRNA expression was achieved in mice. How-
ever, a prominent rebound effect in LRP2 mRNA transcript
expression was observed. The rebound effect, coupled with
the extended half-life of the protein, precluded attaining a
reduction in protein expression. We present the data here in
order to facilitate optimization for other investigators. Target
selection is important. We conclude that the prevention of
upregulated expression holds greater feasibility than knock-
down of a constitutively expressed protein.
2. Methods
2.1. Cell Culture. Mouse S1 proximal tubular (mS1PT) cells
were previously isolated from a mouse carrying the SV40
large T-antigen transgene [26, 27]. BUMPT mouse proximal
tubular cells were a gift from the Patrick Cunningham Lab-
oratory. Cells were maintained in DMEM/F12 (S1) medium
(Corning Cellgro, Corning, NY, USA) supplemented with
10% fetal bovine serum (HyClone) and 1% penicillin-
streptomycin (MP Biomedicals, Santa Ana, CA, USA). Cells
were split when they reached 70–80% confluence and diluted
to 20–30% confluency thrice weekly.Mouse proximal tubular
cells were maintained at 37∘C in 95% humidified atmosphere
with 5% CO
2
.
2.2. siRNA Nucleofection. mS1PT cells were diluted to
500,000 cells/ml one day prior to nucleofection. Cells were
nucleofected using the SF Cell Line Amaxa X-system Nucle-
ofector Kit (Lonza, Inc., Basel, Switzerland) and the CA-137
program on Lonza’s 4D-Nucleofector Amaxa X-system. Cells
were then centrifuged at 90 g for 10min at room temperature
and resuspended at a concentration of 1,000,000 cells/20 𝜇l in
SF/supplement solution (SF Kit, Lonza Catalog V4SC2096)
and 2000 nM final total siRNA concentration for one of
seven conditions. The seven conditions included (1) All Stars
Negative Control siRNA (Qiagen, Inc., Valencia, CA, USA)
at 2000 nM concentration, (2) a pool of four Dharmacon
siLRP2 constructs at a 500 nM concentration for each siRNA
molecule, (3) through (6) each of the four individual Dhar-
macon siLRP2 constructs at a 2000 nM concentration (GE
Dharmacon, Lafayette, CO, USA), or (7) an Ambion in vivo
siLRP2molecule at a 2000 nM concentration (Thermo Fisher
Scientific,Waltham,MA, USA). Cells were allowed to rest for
10min prior to the addition of prewarmed (37∘C water bath)
S1 media and then for another 5min in the warm S1 media.
Cells were then plated for mRNA harvest or drug treatment.
mS1PT cells were harvested 24, 48, 72, 96, 120, and 144 h after
nucleofection for mRNA expression measurements.
2.3. Animals and siRNA Administration. Sixty-nine male
C57BL/6NHsd and eight Swiss Webster mice were obtained
and studied at 6–8wk of age (Envigo Laboratories, Indi-
anapolis, IN, USA). All experimentation was approved by the
Institutional Animal Care and Use Committee (IACUC) at
Indiana University School of Medicine.
Optimization of administration site and carrier solution
was assessed. All animals received injections of Ambion
in vivo siLRP2, molecular grade phosphate-buffered saline
(PBS) vehicle, Invivofectamine (IVFM) vehicle (IVF3005,
Thermo Scientific,Waltham,MA,USA), or scrambled siRNA
(On-Target Plus Control Nontargeting siRNA #2 D-001810-
02-20, Thermo Scientific). Administrations were provided
through tail vein injections, direct intrajugular (IJ) vein injec-
tions, or IJ intravenous catheter infusions. All animal studies
were conducted with in vivo siLRP2 and animals received
doses of either 7.5mcg/gm or 15mcg/gm body weight. These
doses corresponded to concentrations of 0.75mcg/𝜇l or
1.5mcg/𝜇l siLRP2 prepared in either Invivofectamine or PBS
according to themanufacturer’s instructions.The initial start-
ing dose of 7.5mcg/gm body weight was selected to match
Ambion’s recommended starting dose of in vivo siRNA. This
dose was also compared to previously published studies of
siRNAdelivery inmicewhichwere effective at achieving gene
knockdown [10–14]. C57BL/6 mice (20 g weight) were used
for all experiments except the 3.5-day serial siRNA adminis-
tration, in which the larger Swiss Webster mice (35 g weight)
were employed to tolerate larger daily volumes of siRNA
or vehicle. Mice were euthanized by exsanguination and
cervical dislocation at appropriate time points with collection
of blood, kidney tissue, liver tissue, and lung tissue. Three
mice died prior to experimental endpoints due to surgical
mortality or because they required euthanasia for catheter-
related malfunctions.
2.4. Jugular Venous Catheter Placement. Mice were anes-
thetized with isoflurane. Hair was removed from the surgical
site by clippers followed by the hair remover lotionNair (CVS
Pharmacy, Woonsocket, RI, USA) and then disinfected three
times with alternating scrubs of iodine and 70% alcohol. A
5–8mm longitudinal incision was made on the ventral sur-
face of the neck, 5mm right of the midline. The right jugular
vein was exposed and then catheterized by a polyurethane
mouse jugular vein catheter (ID, 0.43mm;OD, 0.69mmwith
a collar of 0.9mm OD, from Instech Laboratories, Inc., Ply-
mouthMeeting, PA, USA) preinfused with PBS.The catheter
was secured in place by suturing around the cannulated
jugular vein and surrounding tissue, and its free end was
connected to a 25 ga PinPort (Instech Laboratories). The
catheter and PinPort were tunneled subcutaneously around
the neck and exteriorized from the dorsal side. The exposed
PinPort was secured on the skin with two sutures and 3M
Vetbond surgical glue (Revival Animal Health, Orange City,
IA, USA). After surgery, the catheter was flushed with PBS
twice daily.
2.5. Tissue Collection, Fixation, and Freezing. Kidneys were
fixed or frozen for routine histologic analysis, immuno-
histochemistry, immunoblot, and real-time PCR. Kidneys
were obtained at sacrifice, cut transversely, and fixed in
formalin or the cortex was isolated and flash-frozen in
Eppendorf tubes with liquid nitrogen. The frozen kidney
cortex was stored at −80∘C for subsequent quantitative real-
time polymerase chain reaction (qRT-PCR) and immunoblot
analysis. For formalin-fixed tissue, specimens were stored in
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Table 1: Primer sequences.
Molecule Sequence (5󸀠-3󸀠)
LRP2 F primer CCT TGC CAA ACC CTC TGA AAA T
LRP2 R primer CAC AAG GTT TGC GGT GTC TTT A
18S F primer GTT GGT GGA GCG ATT TGT CT
18S R primer GAA CGC CAC TTG TCC CTC TAT
4% phosphate-buffered formalin for 6 hours prior to transfer
to 70% ethanol. Specimens were then brought to the core
pathology lab for embedding, cutting, and immunohisto-
chemistry or periodic acid-Schiff (PAS) staining.
2.6. Quantitative Real-Time PCR. qRT-PCR was performed
to measure the levels of expression of LRP2 in mS1PT cells
or in mouse kidney cortex. For cell experiments, a total of
1 million cells were pelleted 24, 48, 72, 96, 120, and 144 h
after nucleofection, washed in ice-cold PBS, and centrifuged
to remove PBS. All pellets were flash-frozen and stored at
−80∘C until RNA isolation. Total RNA was extracted using
themiRNeasy PlusMini Kit (Qiagen) following themanufac-
turer’s protocol. RNA was isolated and purified from frozen
mouse kidney tissue as previously described [28].
RNA quality assessment and quantification were
conducted using the optical spectrometry 260/280 and
260/230 nm ratios. Subsequently, mRNA was reverse
transcribed to cDNA using the Bio-Rad iScript Reverse
Transcription Kit (Bio-Rad, Hercules, CA, USA). The
final concentration of cDNA was 25 ng/𝜇l. qRT-PCR was
performed for LRP2 and 18S (used as an endogenous control)
with custom made primers (Life Technologies, Carlsbad,
CA, USA) and iTaq Universal SYBR Green (Bio-Rad) on
the Applied Biosystems ViiA 7 RT-PCR system. Primer
sequences are provided in Table 1. The entire reaction was
performed in 20𝜇l volume, which consisted of 10 𝜇l SYBR
green, 4 𝜇l cDNA, 0.4 𝜇l of each primer (10 𝜇M stock), and
5.2 𝜇l of water. The thermocycler parameters were 95∘C for
30 s, 40 cycles of 95∘C for 15 s, and then a lower temperature
for 30 s (18S: 60∘C, LRP2: 58∘C), with ramping speeds of
1.6–1.98 C/s and a melt curve. The CT threshold and baseline
for each experiment were set automatically by the ViiA 7
software.
The delta-delta (ΔΔCT) method was used to obtain the
relative expression of each gene. Each sample’s expression
of LRP2 was first subtracted from its 18S expression to
determine its ΔCT. The ΔCTscramble for cell experiments or
the ΔCTcontrol for live animals was then subtracted from the
ΔCTsiRNA to determine the ΔΔCT. Fold change of the siRNA
knockdown as compared to the control was determined by
the formula fold change = 2ΔΔCT. mRNA expression for each
condition is given as a percentage of expression relative to the
control condition.
2.7. Immunoblot. To assess megalin protein expression, pro-
teins were extracted from either an mS1PT cell pellet or a
portion of frozen kidney cortex and stored at −80∘C. Pierce
Radioimmunoprecipitation assay buffer (Pierce Biotechnol-
ogy, Rockford, IL, USA) with 1% Pierce protease inhibitor
(Pierce Biotechnology, Rockford, lL, USA) was used to
prepare protein samples. An immunoblot was performed
with 20 𝜇g of protein per lane (n = 4 per group) on a
NuPAGE 3–8% Tris-Acetate Gel (1.0-mm, 10 wells, Invit-
rogen, Life Technologies, Carlsbad, CA, USA). A goat poly-
clonal antibody to megalin (1 : 500, SC-16478, Santa Cruz
Biotechnology, Inc., Dallas, TX, USA) was incubated for 2
hours at room temperature and a secondary donkey anti-goat
antibody (1 : 5000, SC-2020, Santa Cruz Biotechnology, Inc.)
for 45minutes. As previously described [29], relative megalin
expression was calculated as compared to 𝛽-actin control
(1 : 250, SC-47778, Santa Cruz Biotechnology, Inc.) with
ImageJ software (v1.44p, NIH) [30].
2.8. Immunohistochemistry. Kidney sections were fixed in
10% neutral buffered formalin (EMD Chemicals Inc., Gibb-
stown, NJ, USA) for 6 hours at room temperature and
then transferred to 70% ethanol. Specimens were paraffin-
embedded, sectioned, and stained using the antibody to
megalin (1 : 100, SC-16478, Santa Cruz Biotechnology, Inc.),
followed by a HRP-conjugated secondary antibody donkey
anti-goat (SC-2020, Santa Cruz Biotechnology, Inc.) after
deparaffinization and heat antigen retrieval in citrate buffer.
Tubular staining intensity was scored by pixel density quanti-
tatively using ImageJ software (minimum n = 3 mice, with 10
fields per mouse) and semiquantitatively in terms of intensity
on a scale of 0–3 (0 = none, 1 = weakly positive, 2 = positive,
and 3 = strongly positive).
2.9. Statistics. For cell experiments, statistical significance
was assessed based on a Student’s 𝑡-test for two comparisons
or ANOVA for 3 or more groups. Between control and
siLRP2 treated animals, a Student’s 𝑡-test was used to compare
expression.
3. Results
3.1. siRNA Targeted to LRP2 in S1 Renal Tubular Epithelial
Cells Reduces Relative mRNA Expression. In order to ulti-
mately achieve in vivo knockdown of LRP2, the gene encod-
ing megalin, we began with a series of in vitro experiments to
optimize the siRNA sequence and timing of administration.
Baseline LRP2mRNA expression was screened in twomouse
proximal tubular cell lines,mS1PT andBUMPT, by qRT-PCR.
Baseline raw CT values in mS1PT cells ranged from 22.5 to
23.5, while baseline CT values in BUMPT cells ranged from
28 to 30. Due to their significantly higher mRNA expres-
sion of LRP2, mS1PT cells were selected for downstream
experimentation.
Four siRNA sequences targeting LRP2 were examined
individually and as a pool for their efficacy in reducing LRP2
mRNA expression inmS1PT cells (Figure 1(a)). All sequences
significantly reduced mRNA expression as compared to a
scrambled control siRNA (siSCR). siRNA sequence 4 led to
the most profound reduction in mRNA expression, down
to 16.6 ± 1.0% as compared to the scrambled control (𝑝 =
4.6 × 10−10).
The best performing standard siLRP2 (sequence number
4) was then compared to both the siSCR and a modified
4 Journal of Drug Delivery
Scramble
siRNA 1
siRNA 2
siRNA 3
siRNA 4
Pool of 4 siRNA
siRNA construct
LR
P2
 ex
pr
es
sio
n 
re
lat
iv
e
to
 sc
ra
m
bl
e c
on
tro
l (
%
) 100
125
50
25
75
∗
∗
∗ ∗ ∗
(a)
Scramble
siLRP2 4
In vivo LRP2
siRNA construct
LR
P2
 ex
pr
es
sio
n 
re
lat
iv
e
to
 sc
ra
m
bl
e c
on
tro
l (
%
)
25
50
75
100
125
∗
∗
(b)
Figure 1: In vitro siLRP2 knockdown leads to reduction of mRNA expression in renal S1 proximal tubule cells. (a) All four commercially
available siRNAmolecules targeting LRP2 reduced mRNA expression, individually and as a pool. siRNA #4 led to the strongest knockdown,
reducing mRNA expression to 16.6 ± 1.0% (𝑝 = 4.6 × 10−10). (b) In vivo siLRP2 led to significant knockdown in mS1PT cells as well 15.6 ±
0.9% (𝑝 = 7.2 × 10−8). ∗𝑝 < 0.05 as compared to the scrambled control.
Ambion in vivo siLRP2. Although the Ambion sequence
modifications are proprietary, many siRNA constructs cre-
ated for in vivo application utilize 2󸀠O-methylation mod-
ifications to stabilize the siRNA against degradation [31].
We examined whether these modifications might impact the
efficacy of in vivo siLRP2. Expression was measured by qRT-
PCR (Figure 1(b)) in proximal tubular cells. Both the standard
and in vivo siLRP2 molecules significantly reduced mRNA
expression as compared to siSCR treatment. In vivo siLRP2
outperformed siLRP2 sequence 4 in cell culture, eliciting a
reduction of LRP2mRNA expression to 15.6 ± 0.9% of siSCR
treated expression (𝑝 = 7.2 × 10−8).
3.2. In Vivo siLRP2 Reduces LRP2 mRNA Expression for Days
in Renal Tubular Epithelial Cells. We then sought to deter-
mine the duration of expression reduction in renal tubular
epithelial cells. mS1PT cells treated with in vivo siLRP2 or
siSCR were harvested 24, 48, 72, 96, 120, and 144 hours
following nucleofection and expression was measured by RT-
PCR. LRP2 mRNA expression remained suppressed for 96
hours following nucleofection (Figure 2(a)). Nadir expression
was found 48 h after nucleofection at 11.5 ± 1.0% of scrambled
control expression (𝑝 = 2.0 × 10−6). LRP2 expression was
increased in siLRP2 treated cells as compared to siSCR treated
cells at 144 hours after nucleofection (163.3 ± 2.9%, 𝑝 = 1.3 ×
10−7).
To confirm that knockdown of protein accompanied
mRNA expression reductions in proximal tubular cells, pro-
tein expression of megalin wasmeasured in untreatedmS1PT
cells and in cells 24 and 48 hours after nucleofection by
immunoblot (Figures 2(b)-2(c)). Abundant megalin expres-
sionwas found in siSCRmS1PT cells, but not in those exposed
to siLRP2.
3.3. siLRP2 Reduced Renal mRNA Expression In Vivo. While
prolonged LRP2 mRNA suppression was achieved in renal
cell culture, the degree of exposure time and concentration
of the siRNA in cell culture constructs are unlikely to be
achieved in vivo. Prior in vivo studies have revealed that
fluorescently tagged siRNA targeting P53 remains in contact
with the renal proximal tubule for at least 2 hours. The
siRNA is absent from the nephron at 24 hours, but renal
mRNA expression remains reduced for 24 hours [9].We used
the information obtained from the cell culture experiments
above, prior published literature, and the siRNA manufac-
turer’s guidelines to conduct animal experimentation. All
experimentation was conducted with in vivo siLRP2. In
order to assess its efficacy, mice were given a single dose of
7.5mcg/gm body weight of in vivo siLRP2 or PBS vehicle by
tail vein injection and mRNA expression was measured 24 h
after administration (Figure 3(a)). The dose corresponded to
a 3-fold higher amount as compared to historical doses of
siRNAdelivered to the kidney in PBS [11–13] and corresponds
to the manufacturer’s highest recommended dose. mRNA
expression in mice receiving siLRP2 was not significantly
different from control mice; however an unexpected trend
toward increased LRP2 expression was observed 24 h after
mice received siLRP2 (expression of 135.7 ± 15.1% compared
to control, 𝑝 = 0.084).
We considered that the lack of mRNA expression reduc-
tion with siLRP2 may be secondary to (1) restoration of
mRNA expression at 24 h, (2) inadequate dose, or (3) inef-
ficacy of the siRNA in mice. We then tested the effect of
dose at an earlier time point. Using tail vein injections, mice
received a single dose of one of the following: (1) PBS vehicle,
(2) 7.5mcg/gm in vivo siLRP2, (3) 15mcg/gm in vivo siLRP2,
or (4) an siRNA negative control. mRNA expression was
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Figure 2: LRP2mRNA expression inmS1PT cells is reduced. (a) Knockdown persists for at least 96 h and reaches baseline expression by 120 h
(𝑁 = 3 cell culture experiments). Expression is increased as compared to scrambled (siSCR) expression at 144 h. (b) Megalin immunoblot
reveals decreased protein expression in S1 proximal tubular cells treated with siLRP2. (c) Expression was reduced to 22.4% 24 h after siLRP2
administration and 9.1% 48 h after siLRP2 administration (𝑁 = 2 cell culture experiments). Densitometry was normalized to a beta-actin
control. ∗𝑝 < 0.05 as compared to the siSCR control.
measured 3 h after administration. At 3 h, LRP2 expression
was not significantly different between mice receiving PBS
vehicle and those receiving 7.5mcg/gm siLRP2 (Figure 3(b)).
However, mice receiving 15mcg/gm siLRP2 had 25.2% lower
expression of LRP2 as compared to control mice (expression
reduced to 74.8 ± 6.3%, 𝑝 = 0.034). To confirm expression
reduction was specific to siLRP2 administration, a second set
of control mice were given an in vivo modified scrambled
siRNA (siSCR, nontargeting) as a control. Mice injected with
siSCR did not have significant LRP2 expression reduction.
A trend toward increased LRP2 expression was observed
(139 ± 26.9%, 𝑝 = 0.082) in mice receiving the siSCR
control. Due to the trend toward increased LRP2 expression
in mice receiving the siSCR, PBS vehicle was used as a
control in downstream experimentation in order to be more
conservative with comparisons. Analogously, the 15mcg/gm
siLRP2 dosewas used in downstream applications, a dose that
is 6-fold higher than what most investigators have used to
successfully reduce renal mRNA expression in the past [11–
13].
We then examined the duration of effect of the in vivo
siLRP2 (Figure 3(c)). Mice were given a single dose of siLRP2
at 15mcg/gm or PBS vehicle and sacrificed at 6 h and 12 h
following tail vein administration. At 6 h, LRP2 expression
was reduced to 70.1 ± 6.3% compared to control (𝑝 = 0.015).
At 12 h, LRP2 expression was significantly higher in mice
receiving siLRP2 as compared to control (expression of 160.6
± 11.2% compared to control, 𝑝 = 0.002).
3.4. LRP2 Renal Expression Knockdown Is Not Dependent
upon Administration Site. We considered that siRNA deliv-
ered through tail vein injections would enter hepatic circula-
tion first and this might impact efficacy. Thus, we examined
the difference in degree of mRNA expression reduction in
mice given siLRP2 through tail vein and internal jugular vein
injections. Mice received a single dose of siLRP2 or vehicle
and were sacrificed 3 h after administration. Mice receiving
internal jugular administration of siLRP2 had lower LRP2
expression (55.1 ± 16.0%) as compared to control mice
6 Journal of Drug Delivery
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Figure 3: siLRP2 reduced renal mRNA expression in vivo. (a) At 24 h after 7.5mcg/gm siLRP2 administration, expression of LRP2 was not
reduced in mouse kidney (𝑛 = 5 control, 𝑛 = 4 siLRP2). (b) At 3 h after siLRP2 administration, mice receiving 7.5mcg/gm did not have
LRP2 expression reduction. Mice receiving 15mcg/gm had 25.2% lower LRP2 expression as compared to control (𝑝 = 0.034). Mice receiving
a modified in vivo scrambled siRNA (siSCR) did not have LRP2 expression reduction (𝑛 = 4 per group). (c) At 6 h after 15mcg/gm siLRP2
administration, mice receiving siLRP2 had lower expression of LRP2 as compared to control mice. At 12 h after 15mcg/gm siLRP2, mice had
increased expression as compared to control (𝑛 = 5 control, 𝑛 = 4 siLRP2 at 6 and 12 h). The 3 h expression data from Figure 3(b) is pictured
for reader ease. All siRNA was administered via tail vein and prepared in PBS vehicle. ∗𝑝 < 0.05 as compared to the control or PBS vehicle.
(𝑝 = 0.019). No significant difference in knockdown was
appreciated between mice receiving internal jugular injec-
tions and those receiving tail vein injections (𝑝 = 0.62). In
mice receiving either tail vein or internal jugular injections
of siLRP2, both had significantly lower expression of LRP2
3 h after administration as compared to control mice (Fig-
ure 4(a)).
Internal jugular injections were administered through
direct injection via a cutdown procedure or through an
implanted internal jugular catheter. We compared adminis-
tration from an internal jugular vein cut down or through
an internal jugular catheter (Figure 4(b)). Neither technique
individually reached statistical significance as compared to
control mice due to variability in control LRP2 expression.
LRP2 expression did not significantly vary between tech-
niques. Mice receiving a direct injection of siRNA into the
internal jugular had 38.2 ± 17.0% of control expression and
mice receiving siRNA through a catheter had 62.7 ± 9.2%
Journal of Drug Delivery 7
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Figure 4: LRP2 renal expression knockdown is not dependent upon administration site. (a) Significant knockdown was appreciated in mice
receiving siLRP2 through the internal jugular vein or the tail vein at 3 h (𝑛 = 15 control, 𝑛 = 10 internal jugular (IJ), and 𝑛 = 4 tail vein (TV)).
Control mice include those receiving vehicle by internal jugular or tail vein injection. (b) For mice receiving siLRP2 through the internal
jugular vein, no difference was noted between those receiving direct IJ injections (𝑛 = 3 control and siLRP2) and those receiving siRNA
through an IJ catheter (𝑛 = 7 control, and siLRP2). ∗𝑝 < 0.05 as compared to the control (Ctrl).
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Figure 5: In vivo siLRP2 is effective at reducing LRP2 gene expression in mouse liver. (a) In mouse liver, siLRP2 prepared in the carrier
molecule Invivofectamine (IVFM) had lower measured LRP2 expression than control mice or those receiving siLRP2 in PBS (𝑛 = 5 control,
𝑛 = 6 PBS carrier at 3 h, 𝑛 = 5 IVFM carrier at 3 h, 𝑛 = 3 of IVFM, and PBS at 6 h). (b) Mice receiving siLRP2 by internal jugular (IJ) or tail
vein (TV) injection both achieved reduced LRP2 expression in liver. ∗𝑝 < 0.05 as compared to the control (Ctrl).
expression of control mice (𝑝 = 0.20). Thus, the findings
in Figure 4(a) were pooled from both internal jugular vein
administration procedures to show significant LRP2 knock-
down as compared to control mice.
3.5. In Vivo siLRP2 Is Effective at Reducing LRP2 mRNA
Expression in Mouse Liver. Although significant mRNA
expression knockdown was appreciated in kidney tissue, the
degree of knockdown was modest. Ambion’s in vivo siRNA is
optimized for hepatic expression reduction [32]. In the renal
proximal tubule, siRNAdissolved inmolecular grade PBS can
be reabsorbed via endocytosis after it is filtered through
the glomerulus [9]. In contrast, a carrier molecule is often
required for hepatic uptake [32]. As a positive control for
siRNA efficacy, we examined the degree of LRP2 knockdown
in liver tissue 3 h or 6 h after a single administration of siLRP2
(Figure 5). siRNA was prepared in either PBS or the carrier
molecule, Invivofectamine (IVFM). siLRP2 in PBS carrier
did not lead to a reduction in hepatic LRP2 expression as
compared to control mice at either 3 h or 6 h (89.7 ± 12.0%
expression at 3 h, 𝑝 = 0.61; 113.6 ± 9.4% expression at 6 h,
𝑝 = 0.74). In contrast, siLRP2 in IVFM led to a significant
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Figure 6: Invivofectamine does not improve renal efficacy of
siLRP2. As compared to siLRP2 prepared in PBS, preparing siLRP2
in Invivofectamine did not significantly enhancemRNAknockdown
(𝑛 = 3 to 4 per group). Due to the small number of mice used, no
statistical difference was observed as compared to control mice.
reduction in expression down to 16.3 ± 2.6% as compared
to control mouse expression (𝑝 = 0.0014). The expression
reductionwas still present 6 h after administration (reduction
to 16.6 ± 4.6%, 𝑝 = 0.011).
We tested whether administration site impacted hepatic
LRP2 knockdown at 3 h. Tail vein siLRP2 administrationwith
Invivofectamine reduced expression to 16.3 ± 3.0% (𝑝 =
0.0016) and internal jugular administration reduced expres-
sion to 16.5 ± 9.5% (𝑝 = 0.010) of control expression. No
difference was observed between the administration sites
(𝑝 = 0.94).
LRP2 expression was also measured in lung tissue and
whole blood at 3 h and 6 h after siLRP2 administration.
However, raw baseline expression CT values ranged from
31 to 35 and were undetectable in some specimens. No
conclusions could be drawn regarding knockdown effect in
these tissues.
3.6. Invivofectamine Does Not Improve Renal Efficacy of
siLRP2. Since siLRP2 prepared in Invivofectamine led to
a significant and impressive knockdown in hepatic tissue,
we examined whether this carrier molecule could improve
reduction of expression in the kidney.Micewere given siLRP2
through the internal jugular vein and sacrificed 3 h later for
expression measurements (Figure 6). siRNA was prepared in
either PBS or Invivofectamine. Compared to control mice,
siLRP2 in Invivofectamine did not significantly reduce renal
expression of LRP2 (expression reduced to 73.5 ± 41.4% of
control expression, 𝑝 = 0.72). siLRP2 in PBS reduced mRNA
expression at a similar magnitude to previous experiments at
60.8 ± 20.0% expression of control (also nonsignificant with
𝑝 = 0.11).
3.7. siLRP2 Did Not Reduce Renal Megalin Protein Expression.
We studied the effect of siLRP2 administration on renal
cortical protein expression of 600 kDa megalin (Figure 7).
Mice were given either vehicle or siLRP2 in PBS through an
IJ catheter and sacrificed at 3 h or 12 h after administration.
LRP2 expression was provided in Figure 3(c). We assessed
protein expression by immunohistochemistry. By quantita-
tive analysis with ImageJ, immunohistochemical staining for
megalin revealed unchanged cortical expression in proximal
tubules (𝑝 = 0.27 and 0.33 compared to control, resp.).
Blindedmicroscopy supported this finding (𝑝 = 0.65 and 0.14
compared to control, resp.). Immunoblot of cortical kidney
protein extract revealed unchanged protein expression at
both time points.
Wehypothesized that serial administration of siLRP2may
be required to reduce megalin expression. siLRP2 in PBS was
administered every 12 hours via an IJ catheter for seven total
doses. Mice were sacrificed 3 h after the seventh dose on day
4 (D4) and compared to mice receiving vehicle alone for
3.5 days. Megalin protein expression remained unchanged as
measured by quantitated ImageJ IHC (𝑝 = 0.30), blinded
microscopy (𝑝 = 0.22), and protein immunoblot with
densitometry (𝑝 = 0.72).
4. Discussion
In this investigation, we sought to determine whether in
vivo administration of siRNA would succeed in reducing
expression of the constitutively expressed gene, LRP2, and
its associated protein, megalin. This endeavor builds upon
several prior investigations [10–14].These investigations have
succeeded in preventing upregulation of gene expression in
response to a stimulus or disease state. In contrast, we were
able to reduce baselinemRNA expression, using 6-fold higher
doses of siRNA. Reduction of LRP2 expression was attained
in mice, but a concomitant protein expression decrease was
not observed, even after serial administration. A number
of factors may contribute to this finding, including (1) the
high proportion of membrane-bound protein as compared
to cytoplasmic protein, (2) the modest degree of mRNA
reduction, (3) the rapid rebound and increase in mRNA
expression following siRNA delivery, and (4) the relatively
long half-life of the protein (4.8 h) [25].These results support
the theoretical use of siRNA to transiently reduce baseline
expression of transcripts in the kidney; however, the results
also suggest that the practical application of this technique
will prove difficult.
Our results build upon the existing body of literature.
We have shown that LRP2 rapidly rebounds to a level
of mRNA expression which is significantly above baseline
expression. This finding has been previously reported in
mice for other genes. For example, RNAi targeting the
secretory hepatitis B virus surface antigen gene led to an
initial gene knockdown followed by an expression rebound
[33].The authors identified upregulation of themeri-1 (mouse
enhanced RNAi) and adar-1 (adenosine deaminase acting on
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Figure 7: Continued.
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Figure 7: siLRP2 did not reduce renal megalin protein expression 3 h or 12 h after a single dose. (a) Immunohistochemistry (IHC) of a control
mouse. (b) IHC 3 h after administration of siLRP2. (c) IHC 12 h after administration of siLRP2. (d) IHCof a controlmouse after 3.5 days of PBS
vehicle. (e) IHC 3 h after a final seventh administration of siLRP2. (f) IHC staining density as quantified showed no significant difference;
IHC staining density by visual scoring also revealed no significant difference. (g) Immunoblot densitometry of megalin in mice receiving
siLRP2. (h) Immunoblots of megalin and actin for mice.𝑁 = 4 per group for all analyses. Control mice for the 3 h and 12 h time points were
the same and sacrificed 3 h after vehicle administration (all three groups were sacrificed the same day). For IHC, 10 images were scored for
each mouse. All images 20x, measurement bar is 50 𝜇m.
RNA) genes as a potential mechanistic explanation. One key
difference is that themRNA rebound effect occurred after 4–7
days of knockdown. In contrast, we identified rebound and
upregulation as early as 12 h following administration.
Several limitations affect the generalizability of our
results. Foremost amongst these limitations was the inability
to reduce protein expression. As we discuss above, the
membrane to cytoplasm ratio of the protein, modest mRNA
knockdown effect, rapid rebound effect, and prolonged half-
life all contributed to siRNA inefficacy. However, several
unique features of megalin and LRP2 may additionally con-
spire to impair gene and protein knockdown. First, megalin
has been shown to mediate uptake of siRNA in proximal
tubule cells [34]. While this may appear counterintuitive
to knock down the very protein responsible uptake, in this
scenario, it is unlikely to have had a remarkable effect since (1)
megalin’s uptake capacity is high, and (2) protein expression
reduction was never achieved. A second factor that may have
affected efficacy is the rapid and repetitive recycling of the
protein [25]. Megalin recycles from the cytoplasm to the cell
membrane every 1.2 minutes. This factor should not have
changed megalin’s degradation half-life of 4.8 h, but it might
affect gene expression regulation. Megalin mRNA expression
has been shown to be regulated by its compartmental protein
expression [35]. Overexpression of both the membrane-
bound megalin COOH-terminal fragment (MCTF) and
the soluble megalin intracellular domain (MICD) lead to
significantly lower levels of megalin mRNA. Of note, the
antibody used in our study maps to the carboxy-terminal of
megalin. MCTF is cleaved by gamma-secretase into MICD
and inhibition of gamma-secretase has been showed to
restore megalin mRNA expression in MCTF overexpressed
proximal tubular cells. Since blocking formation of MICD
leads to increased megalin gene and protein expression, the
opposite may hold true.Thus, if soluble intracellular megalin
levels are decreased by siRNA, it follows that wemight expect
a significant counterregulatory increase in gene and protein
expression.
Ultimately, we were not able to reach our goal of
using siLRP2 as a therapeutic alternative to cilastatin or
RAP. Both cilastatin and RAP have been used to block
or decrease expression of megalin in the proximal tubule,
preventing reabsorption of nephrotoxic compounds [21, 22].
Several alternative approaches can be considered in future
experimentation. Nanocarrier molecules [15, 16] have been
used to enhance renal delivery and efficacy of siRNA.
These molecules have been used to prevent upregulation of
expression in response to injury or disease but are not yet
widely available. Their use holds potential to improve the
degree of mRNA expression reduction. However, increased
degree of knockdown does not overcome other factors like
the extended protein half-life, rapid recycling to and from
the membrane, rebound mRNA expression, and complex
regulation of expression by the intracellular protein levels.
Approaches that might counterbalance the half-life and
rebound expression include a continuous infusion of siRNA
or more frequent dosing. The 12-hour time point for serial
administrationwas chosen because of volume administration
limitations, feasibility, and cost. The mRNA rebound phe-
nomenon observed may have impaired the ability to achieve
protein knockdown. While it is possible that a continuous
infusion or more frequent dosing of siRNA would succeed
in reducing megalin protein expression, cilastatin and RAP
are better alternatives to focus on to reduce nephrotoxicity.
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Since both cilastatin andRAP can be administered once daily,
siLRP2 is not an efficient or cost-effectivemeans of preventing
nephrotoxicity.
5. Conclusions
In conclusion, we demonstrated that siLRP2 administration
was sufficient to modestly reduce renal mRNA expression
in mice. This mRNA reduction did not lead to a reduction
in megalin protein expression. A number of very strong
publications have illustrated the use of siRNA to mitigate
renal injury. Publication bias of positive results remains rele-
vant in biomedical research. Although this investigation was
encumbered by a number of limitations, we believe the data
presented will assist other investigators in optimizing future
RNAi experimentation with the kidney. The RNAi thera-
peutic approach may remain more suited to prevention of
upregulation than reduction of baseline mRNA expression.
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